WO2011102444A1 - 誘導多能性幹細胞の製造方法 - Google Patents
誘導多能性幹細胞の製造方法 Download PDFInfo
- Publication number
- WO2011102444A1 WO2011102444A1 PCT/JP2011/053457 JP2011053457W WO2011102444A1 WO 2011102444 A1 WO2011102444 A1 WO 2011102444A1 JP 2011053457 W JP2011053457 W JP 2011053457W WO 2011102444 A1 WO2011102444 A1 WO 2011102444A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gene
- mir
- cells
- pluripotent stem
- microrna
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/65—MicroRNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
- C12N2506/1384—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from adipose-derived stem cells [ADSC], from adipose stromal stem cells
Definitions
- the present invention mainly relates to a method for producing induced pluripotent stem cells using nucleic acids, particularly microRNAs.
- Regenerative medicine is a field in which development is greatly desired as a medical means that can be expected to recover from a situation in which a part of the body is lost to a range where natural healing does not reach due to an accident or disease.
- tissue or the like can be regenerated from a patient-derived cell and transplanted, the problem of immune rejection is eliminated, and the burden on both the patient and the medical institution is greatly reduced. So far, in some tissues such as skin and cornea, development of treatment methods using regenerative medicine has been promoted.
- regenerative medicine is not applicable to all organizations.
- One of the obstacles to the development of regenerative medicine has been the difficulty in obtaining cells with pluripotency and self-replicating ability that can differentiate into any cell, tissue or organ.
- stem cells In humans after the fetal stage, there are stem cells that can differentiate into limited cells and tissues and can self-replicate, but there are no pluripotent stem cells that have pluripotency and self-replication to any cell. .
- ES cell embryonic stem cell
- iPS cells induced pluripotent stem cells
- Sox2, c-Myc and Klf4 genes of Oct3 / 4, Sox2, c-Myc and Klf4, which are nuclear reprogramming factors, into somatic cells.
- induced pluripotent stem cells produced by this technology have been pointed out as important problems for clinical application, such as tumorigenesis of transplanted cells and low production efficiency of induced pluripotent stem cells. Yes.
- As a cause of oncogenesis it has been pointed out that the introduction of the proto-oncogene c-Myc gene and the introduction of the transgene into the genome induces new mutations that cause cancer. Yes.
- the low production efficiency of induced pluripotent stem cells requires trial and error by induction with a method other than the method based on genome insertion.
- the main object of the present invention is to provide a method for producing induced pluripotent stem cells with low possibility of tumor formation and high induction efficiency. Furthermore, the present invention relates to an induced pluripotent stem cell inducer and an induced pluripotent stem cell preparation kit for carrying out the above-described method for producing induced pluripotent stem cells, and an inducer capable of producing induced pluripotent stem cells. Another object is to provide a screening method.
- the present inventor has conducted extensive studies to solve the above problems, and surprisingly, as a nuclear reprogramming factor, NANOG gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene, LIN28 gene, and c-MYC It has been found that induced pluripotent stem cells can be produced regardless of gene integration by introducing into a cell a microRNA that enhances the expression of at least one gene selected from the group consisting of genes. Surprisingly, it has also been revealed that the production method can produce induced pluripotent stem cells not only by gene integration but also with low possibility of tumor formation with high induction efficiency. The present invention has been completed by further studies based on such findings.
- this invention includes the invention of the aspect hung up below.
- Item 1 A method for producing an induced pluripotent stem cell comprising a step of introducing a nuclear reprogramming factor into a somatic cell, wherein the nuclear reprogramming factor is NANOG gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene, LIN28 gene And a method for producing induced pluripotent stem cells, which is a nucleic acid that enhances the expression of at least one gene selected from the group consisting of c-MYC genes.
- Item 2. The method according to Item 1, wherein the nucleic acid is microRNA.
- the at least one selected from the group consisting of microRNA that suppresses differentiation, microRNA that promotes undifferentiation induction, microRNA that controls intercellular adhesion, and microRNA that suppresses apoptosis Item 3.
- Item 5. An induced pluripotent stem cell produced by the method according to any one of Items 5 and 1-4. Item 6.
- Induced pluripotent stem cell comprising a nucleic acid that enhances the expression of at least one gene selected from the group consisting of NANOG gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene, LIN28 gene, and c-MYC gene Inducing agent.
- Item 7 Induced pluripotent stem cell comprising a nucleic acid that enhances the expression of at least one gene selected from the group consisting of NANOG gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene, LIN28 gene, and c-MYC gene Production kit.
- Item 8 Induced pluripotent stem cell comprising a nucleic acid that enhances the expression of at least one gene selected from the group consisting of NANOG gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene, LIN28 gene, and c-MYC gene Production kit.
- a method for screening a nucleic acid capable of producing induced pluripotent stem cells comprising the following steps: (1) introducing a test nucleic acid into a somatic cell; (2) a step of culturing the cell into which the test nucleic acid of step (1) has been introduced, and (3) when an induced pluripotent stem cell is induced in the cultured cell of step (2), The step of selecting a nucleic acid as an induced pluripotent stem cell can be produced.
- Item 9 that induced pluripotent stem cells are induced, of at least one gene selected from the group consisting of NANOG gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene, LIN28 gene, and c-MYC gene, Item 9.
- a screening method according to Item 8 wherein the method is detected by enhancing expression.
- Item 10 The screening method according to Item 8 or 9, wherein the nucleic acid is microRNA.
- induced pluripotent stem cells conventionally, in order to produce induced pluripotent stem cells, it was necessary to introduce a gene containing a proto-oncogene into a somatic cell. NANOG gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene
- NANOG gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene By introducing into the cell a nucleic acid that enhances the expression of at least one gene selected from the group consisting of the LIN28 gene and the c-MYC gene, induction with low possibility of tumor formation without introducing the gene Pluripotent stem cells can be generated.
- induced pluripotent stem cells can be produced with high induction efficiency while having such advantages.
- the induced pluripotent stem cells produced by the present invention can be used as a useful tool in regenerative medicine, for example, as a material for artificially producing tissues or organs such as skin, muscle, and nerves. .
- Induced pluripotent stem cells prepared using mouse adipose stem cells by the method of the present invention (Example 1).
- the upper image is a phase contrast image
- the lower image is a fluorescence image of Nanog-GFP.
- the scale bar represents 100 ⁇ m.
- Induced pluripotent stem cells prepared using mouse adipose stem cells by the method of the present invention (Example 2).
- the upper image is a phase contrast image
- the lower image is a fluorescence image of Nanog-GFP.
- the scale bar represents 100 ⁇ m.
- the expression of SSEA1 antigen was detected by immunostaining (Example 4).
- the upper image is a phase contrast image
- the lower image is a fluorescence image.
- the scale bar represents 100 ⁇ m.
- the expression of mouse Oct3 / 4 protein was detected by immunostaining in induced pluripotent stem cells prepared using mouse adipose stem cells by the method of the present invention (Example 4).
- the upper image is a phase contrast image
- the lower image is a fluorescence image.
- the scale bar represents 100 ⁇ m.
- Expression levels of mouse Nanog gene and mouse Oct3 / 4 gene in induced pluripotent stem cells produced using mouse adipose stem cells (ADSC) by the method of the present invention are compared with control mouse adipose stem cells into which microRNA has not been introduced. Comparison was made (Example 5).
- a phase contrast image of untreated human skin fibroblast cells (upper figure) and a phase contrast image of induced pluripotent stem cells produced using human skin fibroblast cells by the method of the present invention (lower figure) are shown ( Example 7).
- the scale bar represents 100 ⁇ m.
- the present invention mainly aims to provide a method for producing induced pluripotent stem cells, an inducer for induced pluripotent stem cells, a kit for producing induced pluripotent stem cells, and a screening method capable of producing induced pluripotent stem cells.
- a manufacturing method an inducer, a kit, and a screening method.
- the induced pluripotent stem cell referred to in the present invention has pluripotency and self-proliferation ability by introducing a pluripotent inducer (nuclear reprogramming factor) for reprogramming somatic cells.
- a pluripotent inducer nuclear reprogramming factor
- it refers to cells derived from somatic cells.
- the method for producing induced pluripotent stem cells of the present invention is a method for producing induced pluripotent stem cells comprising a step of introducing a nuclear reprogramming factor into somatic cells, wherein the nuclear reprogramming
- the factor is a nucleic acid that enhances the expression of at least one gene selected from the group consisting of NANOG gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene, LIN28 gene, and c-MYC gene. is there.
- the manufacturing method of this invention is explained in full detail.
- induced pluripotent stem cells are produced from somatic cells.
- the somatic cell is preferably a normal cell among normal cells and tumor (cancer) cells.
- the type of cell is not particularly limited, and any somatic cell can be used.
- somatic cells used in the present invention include fibroblasts, epithelial cells, muscle cells (for example, those of skeletal muscle or visceral muscle), hepatocytes, bone cells, vascular endothelial cells, brain neurons, glia (oligos).
- Dendro, Stroglia primary spheres derived from various cells including cranial nerves or glia or cancer cells, secondary spheres, tertiary spheres, hereinafter multispheres, peripheral blood or bone marrow derived mononuclear cells, granulocytes, lymphocytes And osteoblasts, osteoclasts, gastric epithelial cells, liver epithelial cells, large and small intestinal epithelial cells, pancreatic cells (endocrine cells such as alpha and beta cells, and exocrine cells), adipose stem cells (ADSC), etc. .
- ADSC adipose stem cells
- fibroblasts, adipose stem cells, and more preferably adipose stem cells are exemplified. From the viewpoint of easy availability of somatic cells, fibroblasts and adipose stem cells are preferably exemplified.
- the somatic cells are appropriately selected from those derived from mammals such as humans, mice, rats, hamsters, rabbits, cats, dogs, sheep, pigs, cows, goats, monkeys, etc., depending on the intended purpose of the induced stem cells.
- mammals such as humans, mice, rats, hamsters, rabbits, cats, dogs, sheep, pigs, cows, goats, monkeys, etc.
- those derived from humans are preferable.
- those derived from any of fetuses, infants, children, and adults can be used.
- somatic cells those extracted from the origin animal may be used, or commercially available products may be used.
- one obtained by proliferating the obtained somatic cell by a known technique can be used.
- any somatic cell derived from the patient himself or another person can be used.
- Preparation of induced pluripotent stem cells using somatic cells derived from the patient himself is suitable for preparing induced pluripotent stem cells that do not show immune rejection to patients.
- Producing induced pluripotent stem cells using somatic cells derived from others is suitable for producing induced pluripotent stem cells that do not have a genetic disease possessed by a patient.
- the nucleic acid that is a nuclear reprogramming factor in the present invention is at least selected from the group consisting of NANOG gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene, LIN28 gene, and c-MYC gene, which are inherent in the aforementioned somatic cells. As long as it enhances the expression of one gene, it can include DNA and RNA, and is not particularly limited. Specific examples of the nucleic acid include low molecular weight RNA of about 18 to 120 bases, preferably about 18 to 80 bases, more preferably about 18 to 26 bases, or DNA capable of expressing the low molecular weight RNA. . Particularly preferably, the nucleic acid is the aforementioned low molecular weight RNA.
- the low molecular weight RNA examples include non-coding RNA such as microRNA (miRNA) and siRNA, but are not limited thereto.
- the low molecular weight RNA is a microRNA.
- the DNA capable of expressing the low molecular weight RNA is preferably a known expression vector DNA incorporating a sequence corresponding to the low molecular weight RNA.
- microRNA is mainly single-stranded RNA possessed by animal cells, and is considered to have a function of suppressing the expression of a specific target gene or target gene group.
- MicroRNAs are processed directly into Pri-miRNA (Primary miRNA) and Pre-miRNA resulting from the processing of Pri-miRNA, and then the pre-miRNA is further processed and matured (mature) Is thought to occur.
- Pre-miRNA has a base length of about 60 to 80 bases
- mature microRNA has a base length of about 18 to 26 bases.
- the nucleic acid of the present invention is a microRNA
- any of a precursor Pri-miRNA or Pre-miRNA or a mature microRNA can be used as the microRNA.
- the microRNA is preferably Pre-miRNA or mature microRNA, more preferably mature microRNA.
- siRNA is a double-stranded RNA consisting of about 21-23 base pairs. siRNA is considered to cause a phenomenon called RNA interference (RNA interference) that suppresses expression of a gene encoded by the mRNA by destroying the target mRNA.
- RNA interference RNA interference
- a nucleic acid that enhances the expression of at least one gene selected from the group consisting of NANOG gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene, LIN28 gene, and c-MYC gene is introduced into somatic cells.
- the nucleic acid of the present invention is particularly limited as long as it enhances the expression of at least one gene selected from the group consisting of NANOG gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene, LIN28 gene, and c-MYC gene. It is not a thing.
- the nucleic acid is preferably a nucleic acid that enhances the expression of the NANOG gene and / or the OCT3 / 4 gene, and more preferably a nucleic acid that enhances the expression of the NANOG gene. Moreover, it is desirable that the gene is endogenous to somatic cells.
- the NANOG gene encodes a transcription factor having a homeodomain and is specifically expressed in germline cells during mammalian development and plays an important role in maintaining the self-renewal and pluripotency of germline cells. It is considered.
- the SOX2 (SRY (sex determining region Y) -box 2) gene encodes a transcription factor having an HMG box.
- the OCT3 / 4 (also known as POU5F1) gene encodes a transcription factor having a POU-type homeodomain, and is known to be specifically expressed in germline cells during mammalian development. SOX2 and OCT3 / 4 transcription factors are capable of forming dimers and are thought to contribute to the suppression of germline cell differentiation induction.
- the KLF4 (Kruppel-Like Factor 4) gene encodes a transcription factor that is homologous to the transcription factor encoded by the Drosophila Kruppel gene, and the KLF4 transcription factor regulates cell differentiation by controlling cell cycle-related factors. It is known to have The LIN28 gene is homologous to the lin-28 gene of the nematode C. elegans, and is thought to encode an RNA-binding protein that plays an important role in maintaining stem cell pluripotency.
- the c-MYC gene encodes a transcription factor having a bHLH motif and a leucine zipper motif, and the c-MYC transcription factor is considered to be involved in the expression of a wide range of genes.
- the c-MYC gene is also known as a proto-oncogene that becomes an oncogene by mutation.
- Techniques for generating induced pluripotent stem cells include the Oct3 / 4 gene, Sox2 gene, c-Myc gene and Klf4 gene in mice, and the NANOG gene, OCT3 / 4 gene, SOX2 gene and LIN28 gene in humans. Methods for introduction into somatic cells have been reported (Patent Document 1, Non-Patent Document 1). That is, it is considered that the gene plays an important role for cells to have self-replicating ability and / or pluripotency.
- the NANOG gene and the OCT3 / 4 gene that are specifically expressed in germline cells are considered to play an extremely important role in acquiring self-replication ability and pluripotency.
- the nucleic acid of the present invention may be used alone or in combination of two or more.
- the nucleic acid of the present invention may be a combination of different types of nucleic acids such as RNA and DNA, or a combination of different types of RNA such as a combination of microRNA and siRNA.
- NANOG gene Efficiently at least one gene selected from the group consisting of NANOG gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene, LIN28 gene, and c-MYC gene, preferably NANOG gene and / or OCT3 / 4 gene, more preferably From the viewpoint of enhancing the expression of the NANOG gene, it is preferable to use a combination of two or more nucleic acids. Also, from the viewpoint of achieving high pluripotency induction efficiency, in order not to reduce the effect of individual nucleic acids included in the combination, a combination of 10 or less nucleic acids, preferably a combination of 7 or less nucleic acids is used. It is preferable to use it.
- nucleic acid of the present invention is microRNA or DNA capable of expressing microRNA, although not particularly limited, a nuclear reprogramming factor introduced into a cell to produce induced pluripotent stem cells, It can be substantially only the microRNA or only the DNA capable of expressing the microRNA.
- the production method of the present invention includes a step of introducing the microRNA or DNA capable of expressing the microRNA into a somatic cell, and an initialization factor other than DNA capable of expressing the microRNA or microRNA (for example, A compound that can produce induced pluripotent stem cells by using a single or a combination of microRNA or a nucleic acid other than DNA capable of expressing microRNA, a protein, or the like can be a production method that is not substantially introduced into somatic cells.
- substantially not introduced into somatic cells means that an amount of somatic cell reprogramming effects is not introduced into somatic cells.
- the nucleic acid of the present invention is microRNA
- the microRNA that enhances the expression of the OCT3 / 4 gene, more preferably the NANOG gene can be appropriately selected by those skilled in the art by a known method or the like. The same applies when the nucleic acid of the present invention is DNA capable of expressing microRNA.
- the microRNA is expressed in at least one cell selected from undifferentiated cells such as ES cells and cancer cells generally known to have acquired pluripotency and self-replication ability. It is preferable to use RNA, and it is more preferable to use microRNA whose expression level is fluctuating (enhanced or decreased, more preferably enhanced) in the cell as compared with normal differentiated cells.
- the type of undifferentiated cell is not particularly limited, but is preferably a human or mouse ES cell.
- the type of cancer cell is not particularly limited, and examples thereof include colorectal cancer cells, colon cancer cells, esophageal cancer cells, gastric cancer cells, pancreatic cancer cells, liver cancer cells, bile duct cancer cells and the like. .
- NANOG gene for example, miR-17, miR-21, miR-154, miR-200, miR-294, miR-302, miR-367, miR-369
- Examples include at least one selected from miR-370, miR-371, miR-372, miR-373, miR-374, miR-376 (also known as miR-368) and miR-424, preferably miR- Examples include at least one selected from 17, miR-154, miR-200, miR-294, miR-302, miR-367, miR-369, and miR-370.
- pluripotent stem cells have differentiation pluripotency and self-proliferation ability, select from the group consisting of NANOG gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene, LIN28 gene, and c-MYC gene
- MicroRNA that enhances the expression of at least one gene preferably NANOG gene and / or OCT3 / 4 gene, more preferably NANOG gene
- Group B microRNA that promotes undifferentiation induction
- Group C microRNA that controls cell-cell adhesion
- Group D microRNA that suppresses apoptosis
- the differentiation pluripotency of the somatic cell into which the microRNA has been introduced is further activated, for example, by suppressing the promotion of differentiation.
- the group B microRNA into a somatic cell it is considered that the somatic cell into which the microRNA has been introduced activates the differentiation pluripotency of the somatic cell by promoting the undifferentiated state.
- the group C microRNA into a somatic cell it is considered that the self-proliferation ability of the somatic cell into which the microRNA has been introduced is further activated by releasing contact inhibition or the like.
- the somatic cells into which the microRNA has been introduced are inhibited from cell death by apoptosis, and the survival activity of the cells is relatively increased, so that the self-proliferating ability of the somatic cells is further enhanced. It is thought to activate. That is, the NANOG gene, the SOX2 gene, the OCT3 / 4 gene, depending on the function of activating the somatic differentiation pluripotency and / or self-proliferation ability of the microRNAs of the A group, B group, C group and D group. And at least one gene selected from the group consisting of KLF4 gene, LIN28 gene, and c-MYC gene, preferably NANOG gene and / or OCT3 / 4 gene, more preferably NANOG gene, Conceivable.
- the specific microRNAs of the group A, group B, group C and group D can be appropriately selected by those skilled in the art. Specific examples of each group are listed below, but are not limited to the specific microRNAs listed: Group A: miR-294, miR-302, miR-367, miR-369, miR-370, miR-371, miR-372, miR-373, miR-374, miR-376 (also known as miR-368), miR-424 etc .; Group B: miR-17, miR-369, etc .; Group C: miR-200 and the like; and Group D: miR-17, miR-21 and the like.
- Examples of the microRNA consisting of the combination of C and C include miR-302, miR-369, and miR-200, or miR-294, miR-302, miR-369, and miR-200. However, it is not limited to these.
- microRNA is commonly present in mammals including humans, and those derived from any mammal can be used, but it is desirable to select appropriately according to the origin of the somatic cell to be introduced. For example, when using human-derived somatic cells, it is desirable that the microRNA introduced into the somatic cells is derived from humans.
- Pre-miRNA miR-17 has-miR-17 (human, miRBase accession number MI0000071), mmu-miR-17 (mouse, miRBase accession number MI0000687); miR-21: has-miR-21 (human, miRBase accession number MI0000077), mmu-miR-21 (mouse, miRBase accession number MI0000569); miR-154: has-miR-154 (human, miRBase accession number MI0000480), mmu-miR-154 (mouse, miRBase accession number MI0000176); miR-200: has-miR-200a (human, miRBase accession number MI0000737), mmu-miR-200a (mouse, miRBase accession number MI0000554), has-miR-200b (human, miRBase accession number MI0000342), mmu-miR- 200b (mous
- Mature miRNA miR-17 has-miR-17 (human, miRBase accession number MIMAT0000070), mmu-miR-17 (mouse, miRBase accession number MIMAT0000649); miR-21: has-miR-21 (human, miRBase accession number MIMAT0000076), mmu-miR-21 (mouse, miRBase accession number MIMAT0000530); miR-154: has-miR-154 (human, miRBase accession number MIMAT0000452), mmu-miR-154 (mouse, miRBase accession number MIMAT0000164); miR-200: has-miR-200a (human, miRBase accession number MIMAT0000682), mmu-miR-200a (mouse, miRBase accession number MIMAT0000519), has-miR-200b (human, miRBase accession number MIMAT0000318), mmu-
- NANOG for a plurality of pre-miRNAs or microRNAs whose mature microRNA sequences are known (for example, miR-200, miR-302, miR-369, miR-371, miR-374, etc.) At least one gene selected from the group consisting of a gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene, LIN28 gene, and c-MYC gene, preferably NANOG gene and / or OCT3 / 4 gene, more preferably NANOG gene.
- microRNA having one or more sequences selected from the group consisting of the plurality of sequences can be used.
- miR-200 miR-200c is preferably used, but is not limited thereto.
- miR-302 it is preferable to use a combination of miR-302a, miR-302b, miR-302c and miR-302d, but it is not limited thereto.
- miR-369 miR-369-5p alone or a combination of miR-369-3p and miR-369-5p is preferably used, but is not limited thereto.
- the microRNA has one or several nucleotide sequences within a range that has a function of suppressing the expression of a target gene or gene group that is equal to or equal to or greater than the wild-type microRNA.
- 1 to 10, preferably 1 to 6, more preferably 1 to 4, more preferably 1 to 3, particularly preferably 1 or 2 bases are substituted, deleted, and / or inserted. It can also be a mutated microRNA.
- the nucleic acid of the present invention can be prepared according to a conventional method.
- the nucleic acid can be synthesized by chemical synthesis or enzymatic reaction based on known sequence information.
- the nucleic acid is DNA
- a known recombinant DNA technique can be used.
- the nucleic acid is a microRNA
- it can be prepared by extracting the nucleic acid from any mammalian cell.
- the nucleic acid is low molecular weight RNA, it is preferably prepared by chemical synthesis from the viewpoint of easy control of preparation.
- the introduction of the nucleic acid into somatic cells can be performed by a known method.
- examples of the method for introducing the nucleic acid into a somatic cell include a lipofection method, a microinjection method, and a gene gun.
- the lipofection method is preferable from the viewpoint of introduction efficiency and from the viewpoint of cell return efficiency after the introduction treatment.
- the transfection reagent used when using the lipofection method is not particularly limited as long as the lipofection method can be performed.
- Specific examples of the transfection reagent include Lipofectamine® Reagent (Invitrogen) and Lipofectamine 2000 Reagent (Invitrogen), which are cationic transfection reagents, but are not limited thereto.
- the dosage of the nucleic acid to the somatic cells can be appropriately set by those skilled in the art.
- the low molecular weight RNA (or each low molecular weight RNA when introducing multiple types of low molecular weight RNA into somatic cells) is added to the solution containing the transfection reagent.
- Lipofection can be performed by diluting to about 10 to 50 pM, preferably about 20 to 40 pM, more preferably about 25 to 35 pM, and particularly preferably about 30 pM.
- the somatic cells into which the nucleic acid has been introduced are cultured for about 7 to 35 days, preferably about 14 to 35 days, so that the somatic cells are initialized and induced pluripotent stem cells are produced.
- the Various culture conditions such as a specific culture period, atmosphere, and culture medium are appropriately selected by those skilled in the art within a range that is not particularly limited as long as the somatic cells can grow and induced pluripotent stem cells are produced. be able to.
- FBS Fetal Bovine Serum, fetal bovine serum
- D-MEM medium Dulbecco's Modified Eagle Medium, Dulbecco's modified Eagle medium
- culture can be performed in a known ES cell culture environment.
- a known ES cell culture environment is exemplified by a medium in which an additive is added to FBS-containing D-MEM, but is not limited thereto.
- One or more of the above additives can be selected as necessary from NEAA (Non-Essential Amino Acids, non-essential amino acids), L-glutamine, 2-mercaptoethanol, LIF (Leukemia Inhibitory Factor), etc. It is not limited to.
- the ES cell culture environment may be one in which feeder cells are supplied as necessary. Examples of feeder cells that can be used include, but are not limited to, mouse embryonic fibroblasts (MEF).
- cells induced by induced pluripotent stem cells can be selected from somatic cells into which the nucleic acid has been introduced.
- Such selection of induced pluripotent stem cells can be performed using, for example, the presence or absence of expression of a specific marker gene or increase / decrease in the expression level as an index, or the change in cell morphology as an index.
- examples of the marker gene include NANOG gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene, LIN28 gene, or c-MYC gene.
- a gene whose expression is known in the undifferentiated cells preferably NANOG gene or OCT3 / 4 gene, more preferably NANOG gene can be used.
- the expression of the gene or the increased expression level can be used as an index for selecting induced pluripotent stem cells.
- a known method can be used as a method for detecting the presence / absence of marker gene expression or increase / decrease in the expression level. For example, detection of mRNA of a marker gene by quantitative real-time RT-PCR or Northern analysis, a construct (for example, a fluorescent protein such as green fluorescent protein (GFP) and its modified type) bound to a promoter of the marker gene (for example, detection of the promoter activity of a marker gene by one inserted into the genome of a cell or one held by a cell in a plasmid) and detection of the expression of the gene product of the marker gene by immunocytochemistry are exemplified. However, the present invention is not limited to this.
- a construct for example, a fluorescent protein such as green fluorescent protein (GFP) and its modified type
- a construct in which a fluorescent protein is bound to a promoter of a marker gene For example, when using a somatic cell extracted from a Nanog-GFP mouse in which the reporter construct of the Nanog promoter-GFP gene disclosed in Non-Patent Document 3 is used, the expression of GFP is enhanced. It can be used as an index for selecting induced pluripotent stem cells.
- the gene product of the marker gene is a cell membrane surface molecule
- the induced pluripotent stem cells are sorted by the method using a known cell sorter with the presence or absence of expression of the cell membrane surface molecule or the increase or decrease in the expression level as an index. You can choose.
- the morphological change as an index is not particularly limited as long as selection is possible.
- an embryoid body which is a spherical cell mass formed when culturing pluripotent ES cells or the like, can be used as an index.
- An indicator of morphological changes of cells such as embryoid bodies can be visually confirmed by microscopic observation by a known method, for example.
- the selected cells have the characteristics of pluripotent stem cells.
- confirmation means applied in a known ES cell establishment method can be used. Specific examples include, but are not limited to, detection of stem cell markers, evaluation of differentiation potential, and evaluation of self-replication ability. This evaluation method can also be used as a method for selecting cells induced by induced pluripotent stem cells as described above.
- Stem cell markers to be detected include alkaline phosphatase activity, SSEA1 (Stage-Specific Embryonic Antigen-1) antigen, NANOG, SOX2, OCT3 / 4, KLF4, LIN28, and c-MYC genes or proteins encoded by these genes Although expression etc. are illustrated, it is not limited to this. Although a specific detection method is known, for example, detection by immunocytochemistry is preferable.
- a differentiation-inducing factor is added to the medium when culturing the cells, and detection of the differentiation to the target cell type is achieved, or the cells are derived from the body of the derived animal.
- Examples of observation of transplantation into (for example, subcutaneous) and formation of teratomas (teratomas) are exemplified, but the present invention is not limited thereto.
- the above cells are transplanted into a placental vesicle of an animal derived from the above, and verification that a chimeric progeny having the cell derived cell is born, and more preferably, a progeny having the cell derived cell is born by mating with the chimeric organism. Can be verified.
- the above cells can be subcultured, and the growth of the cells and the characteristics of the cells after the proliferation can be used as an index. It is not limited.
- the tumor formation rate of the cells can be evaluated.
- a known method can be used. For example, transplantation into the body (for example, subcutaneous) of the above-mentioned cell in the animal body to evaluate the presence or absence of tumor formation. Can do.
- Induced pluripotent stem cell inducer and induced pluripotent stem cell preparation kit As described above, in the method for producing induced pluripotent stem cells including the step of introducing a nuclear reprogramming factor, the NANOG gene, SOX2 gene, OCT3 / A nucleic acid that enhances the expression of at least one gene selected from the group consisting of 4 genes, KLF4 gene, LIN28 gene, and c-MYC gene, preferably NANOG gene and / or OCT3 / 4 gene, more preferably NANOG gene Induced pluripotent stem cells can be prepared by introducing them into somatic cells as nuclear reprogramming factors. Therefore, the present invention further provides an inducer of induced pluripotent stem cells containing the nucleic acid and the use of the nucleic acid for producing the inducer.
- the inducer of the present invention contains a nucleic acid in the column “1. Method for producing induced pluripotent stem cells” above. The details are as described in the column “1. Method for producing induced pluripotent stem cells” above.
- the above inducer is introduced into somatic cells.
- Introduction of the above-mentioned inducer into somatic cells can be performed by a known technique.
- examples of the method for introducing the above-mentioned inducer into somatic cells include lipofection method, microinjection method, and gene gun.
- the lipofection method is preferable from the viewpoint of introduction efficiency and from the viewpoint of cell return efficiency after the introduction treatment.
- the transfection reagent used when using the lipofection method is not particularly limited as long as the lipofection method can be performed.
- Specific examples of the transfection reagent include Lipofectamine® Reagent (Invitrogen) and Lipofectamine 2000 Reagent (Invitrogen), which are cationic transfection reagents, but are not limited thereto.
- the form of providing the inducer include, but are not limited to, a dry powder or pellet solid of the nucleic acid or a solution of the nucleic acid.
- the inducer is at least one gene selected from the group consisting of NANOG gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene, LIN28 gene, and c-MYC gene, preferably NANOG gene and / or OCT3 / 4 gene, More preferably, other components can be included as long as the function of enhancing NANOG gene expression is not impaired.
- the solvent is not particularly limited as long as the function of the inducer is not impaired.
- water, a buffer for example, Tris / EDTA-containing buffer
- physiological saline for example, water, a buffer (for example, Tris / EDTA-containing buffer).
- the present invention provides at least one gene selected from the group consisting of NANOG gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene, LIN28 gene, and c-MYC gene, preferably NANOG gene and / or OCT3 / 4.
- An induced pluripotent stem cell preparation kit comprising a gene, more preferably a nucleic acid that enhances the expression of the NANOG gene is also provided.
- the kit of the present invention comprises the above inducer.
- the kit of the present invention may contain other components as necessary.
- the other component may also be a reagent or instrument necessary for the generation of induced pluripotent stem cells.
- a reagent or instrument for introducing a nucleic acid into a cell for example, a transfection reagent
- a reagent for example, an antibody
- an instrument for selecting an induced pluripotent stem cell for example, a slide glass, a cover crow
- reagents for example, liquid medium
- instruments for example, petri dishes
- the kit of the present invention can be prepared by providing the above components according to a conventional method.
- the present invention also provides a method for screening low molecular weight RNA capable of producing induced pluripotent stem cells, comprising the following steps: (1) introducing a test nucleic acid into a somatic cell; (2) a step of culturing a cell into which the test nucleic acid is introduced in step (1), and (3) when an induced pluripotent stem cell is induced in the cultured cell of step (2), the test low molecular weight A step of selecting RNA as a nucleic acid capable of producing induced pluripotent stem cells.
- step (1) is a step of introducing a test nucleic acid into a somatic cell to obtain a somatic cell into which the test nucleic acid has been introduced.
- somatic cells are not particularly limited as long as the screening method is realized, but somatic cells exemplified in the above-mentioned “1. Method for producing induced pluripotent stem cells” can be used.
- the test nucleic acid to be screened can include DNA and RNA as long as the screening method is realized, and is not particularly limited.
- the test nucleic acid is preferably one that regulates the expression of a gene endogenous to the somatic cell described above. More preferably, the test nucleic acid is a low molecular weight RNA of about 18 to 120 bases, preferably about 18 to 80 bases, more preferably about 18 to 26 bases, or DNA capable of expressing the low molecular weight RNA. Particularly preferably, the test nucleic acid is the aforementioned low molecular weight RNA. Specific examples of the low molecular weight RNA include non-coding RNA such as microRNA (miRNA) and siRNA, but are not limited thereto. Preferably, the low molecular weight RNA is a microRNA.
- the DNA capable of expressing the low molecular weight RNA is preferably a known expression vector DNA incorporating a sequence corresponding to the low molecular weight RNA.
- test nucleic acid is microRNA
- one derived from any mammal can be used, but it is desirable to select appropriately depending on the origin of the somatic cell to be introduced.
- the test microRNA is desirably derived from human.
- test microRNA is expressed in, for example, at least one cell selected from undifferentiated cells such as ES cells and cancer cells generally known to have acquired pluripotency and self-renewal ability. Is a microRNA. Specific examples of such microRNAs are exemplified in the above-mentioned section “1. Method for producing induced pluripotent stem cells”, but are not limited thereto.
- the test microRNA has one or several (for example, 1 to 10, preferably 1 to 6, more preferably 1 to 4) nucleotide sequences with the wild-type microRNA. More preferably, it may be a mutant microRNA in which 1 to 3, particularly preferably 1 or 2 bases are substituted, deleted, and / or inserted.
- test nucleic acid can be obtained by the method exemplified in the column “1. Method for producing induced pluripotent stem cells” above, but is not limited thereto.
- test nucleic acid can be introduced into a somatic cell alone or in combination of two or more. From the viewpoint of efficiently screening using a large number of test nucleic acids to be screened, it is preferable to use a combination of 2 or more, preferably 4 or more, more preferably 6 or more nucleic acids. From the viewpoint of not reducing the effect of the individual nucleic acids contained in the combination, it is preferable to introduce a combination of 10 or less nucleic acids, preferably 7 or less, into somatic cells.
- the specific method for introducing the test nucleic acid into the somatic cell in the step of introducing the test nucleic acid into the somatic cell is not particularly limited as long as the screening method is realized, but the above-mentioned “1.
- the method exemplified in the “Manufacturing method of stem cell” column can be used.
- step (2) is a step of culturing the cells into which the test nucleic acid of step (1) has been introduced.
- the method for culturing the cells is not particularly limited as long as the screening method is realized.
- Method for producing induced pluripotent stem cells” can be used.
- step (3) is a step of selecting a test nucleic acid as a nucleic acid capable of producing induced pluripotent stem cells when induced pluripotent stem cells are induced in the cultured cells of step (2).
- the induction of induced pluripotent stem cells in the cultured cells in the above step (2) can be evaluated using a known method.
- Method for producing induced pluripotent stem cell” above, or a characteristic of a cell as a pluripotent stem cell is described.
- a method for evaluating the provision can be used, but the method is not limited to this.
- the method includes, for example, at least one gene selected from the group consisting of NANOG gene, SOX2 gene, OCT3 / 4 gene, KLF4 gene, LIN28 gene, and c-MYC gene, preferably NANOG gene and / or OCT3 / 4 An increase in the expression of the gene, more preferably the NANOG gene, is detected.
- Inducing induced pluripotent stem cells in the cultured cells of the above step (2) is preferably one or more cases in 1 ⁇ 10 7 cells into which the cells into which the test nucleic acid has been introduced in step (1) have been introduced. More preferably, induced pluripotent stem cells are induced in one or more cells in 1 ⁇ 10 6 cells, particularly preferably in one or more cells in 1 ⁇ 10 5 cells.
- the selected nucleic acid is a combination of two or more nucleic acids, if necessary, one or more nucleic acids are excluded from the combination and / or are not included in one or more combinations And the screening method can be repeated. By the repetition, selection of a nucleic acid essential for producing induced pluripotent stem cells and / or selection of a nucleic acid capable of producing induced pluripotent stem cells with high efficiency can be performed.
- nucleic acids capable of producing induced pluripotent stem cells are screened.
- Example 1 An experiment was carried out in which mouse adipose stem cells (ABSC) were initialized to produce induced pluripotent stem cells.
- ABSC mouse adipose stem cells
- ABSC mouse adipose stem cell
- Example 1 mmu-miR-17 (SEQ ID NO: 1), mmu-miR-21 (SEQ ID NO: 2), mmu-miR-154 (SEQ ID NO: 3), mmu-miR-302a (SEQ ID NO: 5), mmu- miR-302b (SEQ ID NO: 6), mmu-miR-302c (SEQ ID NO: 7), mmu-miR-302d (SEQ ID NO: 8), mmu-miR-367 (SEQ ID NO: 10), mmu-miR-369-5p ( SEQ ID NO: 12) and mmu-miR-370 (SEQ ID NO: 13);
- Example 2 mmu-miR-200c (SEQ ID NO: 4), mmu-miR-294 (SEQ ID NO: 5), mmu-miR-302a (SEQ ID NO: 5), mmu-miR-302b (SEQ ID NO: 6), mmu
- microRNA was diluted at the time of transfection so that the final concentration of each microRNA was 30 pM.
- each somatic cell after transfection was cultured in D-MEM medium containing 10% FBS for 7 days while changing the medium every other day. From day 7 after transfection, mouse fetal fibroblasts were cultured. Cells (treated with mitomycin 10 ug / ml for 2 hours 30 minutes) were seeded on 0.1% gelatin-coated plates as feeder cells, and as ES cell culture environment, 15% FBS, 100uM NEAA, 2mM L- in D-MEM Culturing was performed using a medium supplemented with glutamine, 100 ⁇ M 2-mercaptoethanol, and LIF 1000 U / ml while changing the medium every day.
- Nanog-GFP which is an indicator of pluripotent stem cells
- Nanog-GFP expression is detected, and induction into independently induced pluripotent stem cells is 1 to 4 cases in 4 ⁇ 10 5 cells on the 10th day after introduction of microRNA, on the 16th day. In 8 to 8 cases were observed in 4 ⁇ 10 5 cells (10 independent trials).
- This result is based on the method for producing induced pluripotent stem cells in which each gene encoding Oct3 / 4, Klf4, c-myc and Sox2 is introduced into a mouse somatic cell using a viral vector (day 10). 2 to 4 cases in 4 ⁇ 10 5 cells, and 8 to 4 cases in 4 ⁇ 10 5 cells on the 16th day (see Non-Patent Documents 1 and 3)).
- the method of the present invention realizes induction into induced pluripotent stem cells with high efficiency satisfactory in the medical industry.
- Example 4 It was verified by an immunostaining experiment of a marker protein that the induced pluripotent stem cells of Example 3 have the same properties as ES cells.
- marker proteins to be detected SSEA1 antigen and Oct3 / 4 protein, which are known to specifically express pluripotent cells such as ES cells, were used.
- Example 3 The cells of Example 3 were fixed by immunostaining. Next, the fixed sample was washed at 4 ° C. in a phosphate buffer solution in which anti-SSEA1 antibody (MAB4301, Millpore) was diluted to 10 ⁇ g / ml or anti-mouse Oct3 / 4 antibody (MAB4305, Millpore) was diluted to 20 ⁇ g / ml. Incubate for 24 hours, and after washing, goat-derived Alexa546-labeled anti-mouse IgG antibody (Invitrogen) was diluted with phosphate buffer to 500 ng / ml as a secondary antibody at 37 ° C. for 30 hours. Incubated for minutes to prepare antibody-stained samples. The antibody-stained sample was observed using a Keyence All-in one type fluorescence microscope system.
- MAB4301, Millpore anti-mouse Oct3 / 4 antibody
- Invitrogen goat-derived Alexa546-labeled anti-mouse IgG antibody
- Example 5 It was verified by measuring the expression level of the marker gene that the induced pluripotent stem cells of Example 3 had the same properties as ES cells.
- marker genes to be measured Nanog gene and Oct3 / 4 gene, which are known to specifically express pluripotent cells such as ES cells, were used.
- Example 3 The cells of Example 3, control mouse adipose stem cells cultured in D-MEM medium supplemented with 10% FBS, and the mouse ES cells cultured in an ES cell culture environment similar to the cells of Example 3 As for (R-CMTI-1A, Millpore), the somatic cells of Example 3 on the 25th day after introduction of the microRNA, or control mouse adipose stem cells and mouse ES cells cultured for a period corresponding thereto were collected. .
- Total RNA was extracted from each cell using the mirVana miRNA Isolation Kit (AM1560, Ambion) according to the instructions attached to the kit, and about 2 ⁇ g of total RNA was extracted from each cell.
- mirVana miRNA Isolation Kit AM1560, Ambion
- PCR amplification conditions were as follows: 35 cycles of heat denaturation at 95 ° C. for 10 seconds and annealing and extension reactions at 60 ° C. for 30 seconds. PCR was performed 3 times independently for each sample, and the average of 3 times was used as the expression level.
- the PCR primers used were as follows: (1) Mouse Nanog gene: Nanog-S (SEQ ID NO: 21): 5'-TTCTTGCTTACAAGGGTCTGC-3 ' Nanog-AS (SEQ ID NO: 22): 5'-CAGGGCTGCCTTGAAGAG-3 ' (2) Mouse Oct3 / 4 gene Oct3 / 4-S (SEQ ID NO: 23): 5'-CACGAGTGGAAAGCAACTCA-3 ' Oct3 / 4-AS (SEQ ID NO: 24): 5'- GCTTTCATGTCCTGGGACTC -3 ' (3) Mouse GADPH gene: Gapdh-S (SEQ ID NO: 25): 5'- TGTCCGTCGTGGATCTGAC -3 ' Gapdh-AS (SEQ ID NO: 26): 5'-CCTGCTTCACCACCTTCTTG-3 '
- Example 3 expressed the mouse Nanog gene and the mouse Oct3 / 4 gene in the same manner as ES cells. Therefore, it became clear that the cell which shows the property similar to ES cell was producible by the method of this invention.
- Example 6 The tumor formation rate of the induced pluripotent stem cells of Example 3 was evaluated.
- Example 3 The induced pluripotent stem cells of Example 3 were obtained on day 30 after introduction of microRNA, and control cells cultured in the same manner except for introduction of microRNA, each of 1 ⁇ 10 6 cells containing D containing 10% FBS. -It diluted to 100 microliters of MEM, this was inject
- induced pluripotent stem cells prepared by the method of the present invention have a lower possibility of tumor formation than induced pluripotent stem cells prepared by gene introduction.
- Example 7 An experiment was carried out in which human skin fibroblasts (HDF) were initialized to produce induced pluripotent stem cells.
- HDF human skin fibroblasts
- Hsa-miR-302c (SEQ ID NO: 16), hsa-miR-302d (SEQ ID NO: 17), hsa-miR-369-3p (SEQ ID NO: 18), hsa-miR-369-5p (SEQ ID NO: 19) and hsa -miR-369-3p (SEQ ID NO: 20) was transfected.
- somatic cells after transfection were also cultured in the same procedure as in Examples 1 to 3 above. After the introduction of the microRNA, the cells were observed on the 20th day after the introduction of the microRNA using a Keyence All-inone type fluorescence microscope system.
- SEQ ID NOS: 1-13 are mmu-miR-17, mmu-miR-21, mmu-miR-154, mmu-miR-200c, mmu-miR-294, mmu-miR-302a, mmu-miR-302b, mmu
- the base sequences of mature microRNAs of -miR-302c, mmu-miR-302d, mmu-miR-367, mmu-miR-369-3p, mmu-miR-369-5p and mmu-miR-370 are shown.
- SEQ ID NOs: 14-20 are hsa-miR-200c, hsa-miR-302a, hsa-miR-302b, hsa-miR-302c, hsa-miR-302d, hsa-miR-369-3p and hsa-miR-369 This shows the base sequence of -5p mature microRNA.
- SEQ ID NOs: 21 and 22 show the nucleotide sequences of primers for amplifying the mouse Nanog gene.
- SEQ ID NOs: 23 and 24 show the nucleotide sequences of primers for amplifying the mouse Oct3 / 4 gene.
- SEQ ID NOs: 25 and 26 show the nucleotide sequences of primers for amplifying the mouse GADPH gene.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Developmental Biology & Embryology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
項1、体細胞に核初期化因子を導入する工程を含む誘導多能性幹細胞の製造方法であって、前記核初期化因子がNANOG遺伝子、SOX2遺伝子、OCT3/4遺伝子、KLF4遺伝子、LIN28遺伝子、およびc-MYC遺伝子からなる群から選択される少なくとも1つの遺伝子の発現を亢進させる核酸である、誘導多能性幹細胞の製造方法。
項2、前記核酸が、マイクロRNAである、項1に記載の製造方法。
項3、前記マイクロRNAが、分化を抑制させるマイクロRNA、未分化誘導を促進させるマイクロRNA、細胞間接着を制御するマイクロRNA、およびアポトーシスを抑制するマイクロRNAからなる群より選択される少なくとも1種である、項2に記載の製造方法。
項4、前記マイクロRNAが、miR-200、miR-302、およびmiR-369である項2又は3に記載の製造方法。
項5、項1~4のいずれか1つに記載の方法によって製造される、誘導多能性幹細胞。
項6、NANOG遺伝子、SOX2遺伝子、OCT3/4遺伝子、KLF4遺伝子、LIN28遺伝子、およびc-MYC遺伝子からなる群から選択される少なくとも1つの遺伝子の発現を亢進させる核酸を含む、誘導多能性幹細胞の誘導剤。
項7、NANOG遺伝子、SOX2遺伝子、OCT3/4遺伝子、KLF4遺伝子、LIN28遺伝子、およびc-MYC遺伝子からなる群から選択される少なくとも1つの遺伝子の発現を亢進させる核酸を含む、誘導多能性幹細胞作製キット。
項8、下記の工程を含む、誘導多能性幹細胞を製造できる核酸のスクリーニング方法:
(1)体細胞に被験核酸を導入する工程、
(2)工程(1)の被験核酸が導入された細胞を培養する工程、および
(3)工程(2)の培養された細胞において誘導多能性幹細胞が誘導される場合は、該被験核酸を、誘導多能性幹細胞を製造できるとして核酸選択する工程。
項9、誘導多能性幹細胞が誘導されることを、NANOG遺伝子、SOX2遺伝子、OCT3/4遺伝子、KLF4遺伝子、LIN28遺伝子、およびc-MYC遺伝子からなる群から選択される少なくとも1つの遺伝子の、発現の亢進により検出する項8のスクリーニング方法。
項10、前記核酸が、マイクロRNAである、項8又は9に記載のスクリーニング方法。
本発明の誘導多能性幹細胞の製造方法は、体細胞に核初期化因子を導入する工程を含む誘導多能性幹細胞の製造方法であって、前記核初期化因子がNANOG遺伝子、SOX2遺伝子、OCT3/4遺伝子、KLF4遺伝子、LIN28遺伝子、およびc-MYC遺伝子からなる群から選択される少なくとも1つの遺伝子の発現を亢進させる核酸であることを特徴とするものである。以下、本発明の製造方法について詳述する。
A群:分化を抑制させるマイクロRNA、
B群:未分化誘導を促進させるマイクロRNA、
C群:細胞間接着を制御するマイクロRNA、および
D群:アポトーシスを抑制するマイクロRNA
から選択される少なくとも1種、好ましくは上記A群、B群、およびC群、又は、A群、B群、およびD群、から選択される少なくとも1種、さらに好ましくは上記A群、B群およびC群、又は、A群、B群、およびD群の組み合わせからなるマイクロRNAであるが、これに限定されるものではない。上記A群のマイクロRNAを体細胞で導入することで、分化の促進の抑制などによって、当該マイクロRNAを導入した体細胞の分化多能性をより活性化すると考えられる。上記B群のマイクロRNAを体細胞で導入することで、未分化状態の促進によって、当該マイクロRNAを導入した体細胞が体細胞の分化多能性をより活性化すると考えられる。上記C群のマイクロRNAを体細胞へ導入することで、接触阻止(contact inhibition)の解除などによって、当該マイクロRNAを導入した体細胞の自己増殖能をより活性化すると考えられる。上記D群のマイクロRNAを体細胞へ導入することで、当該マイクロRNAを導入した体細胞はアポトーシスにより細胞死が抑制され、相対的に細胞の生存活性が高まり、体細胞の自己増殖能をより活性化すると考えられる。すなわち、上記A群、B群、C群およびD群のマイクロRNAが有する体細胞の分化多能性および/又は自己増殖能をより活性化する機能によって、NANOG遺伝子、SOX2遺伝子、OCT3/4遺伝子、KLF4遺伝子、LIN28遺伝子、およびc-MYC遺伝子からなる群から選択される少なくとも1つの遺伝子、好ましくはNANOG遺伝子および/又はOCT3/4遺伝子、より好ましくはNANOG遺伝子の発現の亢進が実現されると考えられる。
A群:miR-294、miR-302、miR-367、miR-369、miR-370、miR-371、miR-372、miR-373、miR-374、miR-376(別名:miR-368)、miR-424など;
B群:miR-17、miR-369、など;
C群:miR-200など;および
D群:miR-17、miR-21など。
A群、B群、D群を含むマイクロRNAとして、miR-302、miR-367、miR-369、miR-370、miR-17、miR-21およびmiR-154の組み合わせ、並びに
A群、B群およびC群の組み合わせからなるマイクロRNAとして、miR-302、miR-369、およびmiR-200の組合せ、またはmiR-294、miR-302、miR-369およびmiR-200の組み合わせなどが例示されるが、これらに限定されるものではない。
miR-17:has-miR-17(ヒト、miRBase accession number MI0000071)、mmu-miR-17(マウス、miRBase accession number MI0000687);
miR-21:has-miR-21(ヒト、miRBase accession number MI0000077)、mmu-miR-21(マウス、miRBase accession number MI0000569);
miR-154:has-miR-154(ヒト、miRBase accession number MI0000480)、mmu-miR-154(マウス、miRBase accession number MI0000176);
miR-200:has-miR-200a(ヒト、miRBase accession number MI0000737)、mmu-miR-200a(マウス、miRBase accession number MI0000554)、has-miR-200b(ヒト、miRBase accession number MI0000342)、mmu-miR-200b(マウス、miRBase accession number MI0000243)、has-miR-200c(ヒト、miRBase accession number MI0000650)、mmu-miR-200c(マウス、miRBase accession number MI0000694);
miR-294:mmu-miR-294(マウス、miRBase accession number MI0000392);
miR-302:has-miR-302a(ヒト、miRBase accession number MI0000738)、mmu-miR-302a(マウス、miRBase accession number MI0000402)、has-miR-302b(ヒト、miRBase accession number MI0000772)、mmu-miR-302b(マウス、miRBase accession number MI0003716)、has-miR-302c(ヒト、miRBase accession number MI0000773)、mmu-miR-302c(マウス、miRBase accession number MI0003717)、has-miR-302d(ヒト、miRBase accession number MI0000774)、mmu-miR-302d(マウス、miRBase accession number MI0003718)、has-miR-302e(ヒト、miRBase accession number MI0006417)、has-miR-302f(ヒト、miRBase accession number MI0006418);
miR-367:has-miR-367(ヒト、miRBase accession number MI0000775)、mmu-miR-367(マウス、miRBase accession number MI0003531);
miR-369:has-miR-369(ヒト、miRBase accession number MI0000777)、mmu-miR-369(マウス、miRBase accession number MI0003535);
miR-370:has-miR-370(ヒト、miRBase accession number MI0000778)、mmu-miR-370(マウス、miRBase accession number MI0001165);
miR-371:has-miR-371(ヒト、miRBase accession number MI0000779);
miR-372:has-miR-372(ヒト、miRBase accession number MI0000780);
miR-373:has-miR-373(ヒト、miRBase accession number MI0000781);
miR-374:has-miR-374a(ヒト、miRBase accession number MI0000782)、mmu-374b(ヒト、miRBase accession number MI0005566)、mmu-miR-374, (マウス、miRBase accession number MI0004125);
miR-376(別名:miR-368):hsa-miR-376c(ヒト、miRBase accession number MI0000776)、mmu-miR-376c(マウス、miRBase accession number MI0003533);
miR-424:has-miR-424(ヒト、miRBase accession number MI0001446)。
miR-17:has-miR-17(ヒト、miRBase accession number MIMAT0000070)、mmu-miR-17(マウス、miRBase accession number MIMAT0000649);
miR-21:has-miR-21(ヒト、miRBase accession number MIMAT0000076)、mmu-miR-21(マウス、miRBase accession number MIMAT0000530);
miR-154:has-miR-154(ヒト、miRBase accession number MIMAT0000452)、mmu-miR-154(マウス、miRBase accession number MIMAT0000164);
miR-200:has-miR-200a(ヒト、miRBase accession number MIMAT0000682)、mmu-miR-200a(マウス、miRBase accession number MIMAT0000519)、has-miR-200b(ヒト、miRBase accession number MIMAT0000318)、mmu-miR-200b(マウス、miRBase accession number MIMAT0000233)、has-miR-200c(ヒト、miRBase accession number MIMAT0000617)、mmu-miR-200c(マウス、miRBase accession number MIMAT0000657);
miR-294:mmu-miR-294(マウス、miRBase accession number MIMAT0000372);
miR-302:has-miR-302a(ヒト、miRBase accession number MIMAT0000684)、mmu-miR-302a(マウス、miRBase accession number MIMAT0000380)、has-miR-302b(ヒト、miRBase accession number MIMAT0000715)、mmu-miR-302b(マウス、miRBase accession number MIMAT0003374)、has-miR-302c(ヒト、miRBase accession number MIMAT0000717)、mmu-miR-302c(マウス、miRBase accession number MIMAT0003376)、has-miR-302d(ヒト、miRBase accession number MIMAT0000718)、mmu-miR-302d(マウス、miRBase accession number MIMAT0003377)、has-miR-302e(ヒト、miRBase accession number MIMAT0005931)、has-miR-302f(ヒト、miRBase accession number MIMAT0005932);
miR-367:has-miR-367(ヒト、miRBase accession number MIMAT0000719)、mmu-miR-367(マウス、miRBase accession number MIMAT0003181);
miR-369:has-miR-369-3p(ヒト、miRBase accession number MIMAT0000721)、has-miR-369-5p(ヒト、miRBase accession number MIMAT0001621)、mmu-miR-369-3p(マウス、miRBase accession number MIMAT0003186)、mmu-miR-369-5p(マウス、miRBase accession number MIMAT0003185);
miR-370:has-miR-370(ヒト、miRBase accession number MIMAT0000722)、mmu-miR-370(マウス、miRBase accession number MIMAT0001095);
miR-371、has-miR-371-3p(ヒト、miRBase accession number MIMAT0000723)、has-miR-371-5p(ヒト、miRBase accession number MIMAT0004687);
miR-372、has-miR-372(ヒト、miRBase accession number MIMAT0000724);
miR-373、has-miR-373(ヒト、miRBase accession number MIMAT0000726);
miR-374、has-miR-374a(ヒト、miRBase accession number MIMAT0000727)、mmu-374b(ヒト、miRBase accession number MIMAT0004955)、mmu-miR-374, (マウス、miRBase accession number MIMAT0003727);
miR-376(別名miR-368):hsa-miR-376c(ヒト、miRBase accession number MIMAT0000720)、mmu-miR-376c(マウス、miRBase accession number MIMAT0003183);
miR-424:has-miR-424(ヒト、miRBase accession number MIMAT0001341)。
前述するように、核初期化因子を導入する工程を含む誘導多能性幹細胞の製造方法において、NANOG遺伝子、SOX2遺伝子、OCT3/4遺伝子、KLF4遺伝子、LIN28遺伝子、およびc-MYC遺伝子からなる群から選択される少なくとも1つの遺伝子、好ましくはNANOG遺伝子および/又はOCT3/4遺伝子、より好ましくはNANOG遺伝子の発現を亢進させる核酸を、核初期化因子として体細胞に導入することにより、誘導多能性幹細胞を調製することができる。従って、本発明は、さらに、上記核酸を含む誘導多能性幹細胞の誘導剤および該誘導剤を製造するための上記核酸の使用をも提供する。
さらに、本発明は、下記の工程を含む、誘導多能性幹細胞を製造できる低分子量RNAのスクリーニング方法をも提供する:
(1)体細胞に被験核酸を導入する工程、
(2)工程(1)の被験核酸が導入された細胞を培養する工程、および
(3)工程(2)の培養された細胞において誘導多能性幹細胞が誘導される場合は、該被験低分子量RNAを誘導多能性幹細胞を製造できる核酸として選択する工程。
マウス脂肪幹細胞(ABSC)を初期化して、誘導多能性幹細胞を作製する実験を行った。
Nanog-GFPマウスからマウス脂肪幹細胞(ABSC)株を非特許文献4に記載の方法に従い樹立し、これを培養した。Lipofectamine2000を5μl/ml、並びに下記の組み合わせの化学合成したマイクロRNAを無血清培地で希釈した溶液に、前記ABSCを2×105細胞/mlとなるよう混合し、マクロRNAのトランスフェクションを行った:
実施例1:mmu-miR-17(配列番号1)、mmu-miR-21(配列番号2)、mmu-miR-154(配列番号3)、mmu-miR-302a(配列番号5)、mmu-miR-302b(配列番号6)、mmu-miR-302c(配列番号7)、mmu-miR-302d(配列番号8)、mmu-miR-367(配列番号10)、mmu-miR-369-5p(配列番号12)およびmmu-miR-370(配列番号13);
実施例2:mmu-miR-200c(配列番号4)、mmu-miR-294(配列番号5)、mmu-miR-302a(配列番号5)、mmu-miR-302b(配列番号6)、mmu-miR-302c(配列番号7)、mmu-miR-302d(配列番号8)、mmu-miR-369-3p(配列番号11)およびmmu-miR-369-5p(配列番号12);
実施例3:mmu-miR-200c(配列番号4)、mmu-miR-302a(配列番号6)、mmu-miR-302b(配列番号7)、mmu-miR-302c(配列番号8)、mmu-miR-302d(配列番号9)、mmu-miR-369-3p(配列番号11)およびmmu-miR-369-5p(配列番号12)。
実施例1および2において、マイクロRNA導入後10日目において、Nanog-GFPの発現が検出される細胞が観察された。また、Nanog-GFPの発現が検出される細胞は、多能性幹細胞特有の形態である、球状の細胞塊(胚様体)を形成する細胞が観察された(図1および2)。
実施例3の誘導多能性幹細胞がES細胞と同等の性質を有することを、マーカータンパク質の免疫染色実験により検証した。検出対象のマーカータンパク質として、ES細胞などの多能性を有する細胞が特異的に発現することが知られている、SSEA1抗原およびOct3/4タンパク質を用いた。
実施例3の細胞を、免疫染色法により固定した。次に、固定試料を、抗SSEA1抗体(MAB4301, Millpore社)を10μg/ml又は抗マウスOct3/4抗体(MAB4305, Millpore社)を20μg/mlに希釈したリン酸緩衝液中で、4℃にて24時間インキュベートし、さらに洗浄後、二次抗体としてヤギ由来Alexa546標識抗マウスIgG抗体(Invitrogen社)をリン酸緩衝液で500ng/mlに希釈したリン酸緩衝液中で、37℃にて30分間インキュベートし抗体染色試料を作製した。抗体染色試料をKeyence社All-in oneタイプ蛍光顕微鏡システムを用いて観察した。
図3に示すとおり、図3下図中央部のコロニーにおいてマウスSSEA1抗原の発現が確認された。また、図4に示すとおり、図4下図中央部のコロニーにおいてマウスOct3/4タンパク質の発現が確認された。従って、本発明の方法によって、ES細胞と同様の性質を示す細胞が作製できることが明らかとなった。
実施例3の誘導多能性幹細胞がES細胞と同等の性質を有することを、マーカー遺伝子の発現量の測定により検証した。測定対象のマーカー遺伝子として、ES細胞などの多能性を有する細胞が特異的に発現することが知られている、Nanog遺伝子およびOct3/4遺伝子を用いた。
実施例3の細胞、10%のFBSを加えたD-MEM培地で培養したマイクロRNAを導入しない対照のマウス脂肪幹細胞、および実施例3の細胞と同様にES細胞培養環境で培養したマウスES細胞(R-CMTI-1A, Millpore社)について、マイクロRNAを導入後25日目の実施例3の体細胞、またはこれに相当する期間培養を行った対照のマウス脂肪幹細胞およびマウスES細胞を回収した。それぞれの細胞より、mirVana miRNA Isolation Kit(AM1560, Ambion社)を用いて同キットに添付の手順書に従ってtotal RNAの抽出を行い、それぞれの細胞より約2μgのtotal RNAを抽出した。
(1)マウスNanog遺伝子:
Nanog-S(配列番号21):5’- TTCTTGCTTACAAGGGTCTGC -3’
Nanog-AS(配列番号22):5’- CAGGGCTGCCTTGAAGAG -3’
(2)マウスOct3/4遺伝子
Oct3/4-S(配列番号23):5’- CACGAGTGGAAAGCAACTCA -3’
Oct3/4-AS(配列番号24):5’- GCTTTCATGTCCTGGGACTC -3’
(3)マウスGADPH遺伝子:
Gapdh-S(配列番号25):5’- TGTCCGTCGTGGATCTGAC -3’
Gapdh-AS(配列番号26):5’- CCTGCTTCACCACCTTCTTG -3’
図5に示すとおり、実施例3の誘導多能性幹細胞は、ES細胞と同様にマウスNanog遺伝子およびマウスOct3/4遺伝子を発現していることが確認された。従って、本発明の方法によって、ES細胞と同様の性質を示す細胞が作製できることが明らかとなった。
実施例3の誘導多能性幹細胞の腫瘍形成率を評価した。
実施例3の誘導多能性幹細胞についてマイクロRNA導入後30日目のもの、およびマイクロRNAを導入する以外は同様の培養を行った対照細胞それぞれ1×106細胞を、10%FBSを含むD-MEM100μlに希釈し、これをNOD/SCIDマウスの側腹部の皮下に注入し、マウスを4週間飼育した後に、腫瘍形成能を評価した。
非特許文献3において腫瘍形成が報告される皮下注入後4週間においても、実施例1で作製した誘導多能性幹細胞および対照細胞腫瘍を注入したマウスにおいて、腫瘍の形成が認められなかった(マイクロRNA導入細胞は6例中0例、対照細胞は6例中0例)。
ヒト皮膚線維芽細胞(HDF)を初期化して、誘導多能性幹細胞を作製する実験を行った。
ヒト皮膚線維芽細胞(Human dermal fibroblasts(HDF)(CA106K05a, 東洋紡社))をD-MEM +10%FBS培地で培養した。上記実施例1~3と同様の手順で、化学合成したマイクロRNAのhsa-miR-200c(配列番号13)、hsa-miR-302a(配列番号14)、hsa-miR-302b(配列番号15)、hsa-miR-302c(配列番号16)、hsa-miR-302d(配列番号17)、hsa-miR-369-3p(配列番号18)、hsa-miR-369-5p(配列番号19)およびhsa-miR-369-3p(配列番号20)をトランスフェクトした。
図6下図に示す通り、対照のHDF細胞(図5上図)の形状とは明確に異なる、多能性幹細胞特有の形態である、球状の細胞塊(胚様体)を形成する細胞が観察された。従って、本発明の方法によって、ヒト線維芽細胞を初期化して、誘導多能性幹細胞を作製できることが明らかとなった。
配列番号14~20は、hsa-miR-200c、hsa-miR-302a、hsa-miR-302b、hsa-miR-302c、hsa-miR-302d、hsa-miR-369-3pおよびhsa-miR-369-5pの成熟したマイクロRNAの塩基配列を示す。
配列番号21および22は、マウスNanog遺伝子を増幅するためのプライマーの塩基配列を示す。
配列番号23および24は、マウスOct3/4遺伝子を増幅するためのプライマーの塩基配列を示す。
配列番号25および26は、マウスGADPH遺伝子を増幅するためのプライマーの塩基配列を示す。
Claims (10)
- 体細胞に核初期化因子を導入する工程を含む誘導多能性幹細胞の製造方法であって、
前記核初期化因子がNANOG遺伝子、SOX2遺伝子、OCT3/4遺伝子、KLF4遺伝子、LIN28遺伝子、およびc-MYC遺伝子からなる群から選択される少なくとも1つの遺伝子の発現を亢進させる核酸である、誘導多能性幹細胞の製造方法。 - 前記核酸が、マイクロRNAである、請求項1に記載の製造方法。
- 前記マイクロRNAが、分化を抑制させるマイクロRNA、未分化誘導を促進させるマイクロRNA、細胞間接着を制御するマイクロRNA、およびアポトーシスを抑制するマイクロRNAからなる群より選択される少なくとも1種のマイクロRNAを含むマイクロRNAである、請求項2に記載の製造方法。
- 前記マイクロRNAが、miR-200、miR-302、およびmiR-369である請求項2又は3に記載の製造方法。
- 請求項1~4のいずれか1つに記載の方法によって製造される、誘導多能性幹細胞。
- NANOG遺伝子、SOX2遺伝子、OCT3/4遺伝子、KLF4遺伝子、LIN28遺伝子、およびc-MYC遺伝子からなる群から選択される少なくとも1つの遺伝子の発現を亢進させる核酸を含む、誘導多能性幹細胞の誘導剤。
- NANOG遺伝子、SOX2遺伝子、OCT3/4遺伝子、KLF4遺伝子、LIN28遺伝子、およびc-MYC遺伝子からなる群から選択される少なくとも1つの遺伝子の発現を亢進させる核酸を含む、誘導多能性幹細胞作製キット。
- 下記の工程を含む、誘導多能性幹細胞を製造できる核酸のスクリーニング方法:
(1)体細胞に被験核酸を導入する工程、
(2)工程(1)の被験核酸が導入された細胞を培養する工程、および
(3)工程(2)の培養された細胞において誘導多能性幹細胞が誘導される場合は、該被験核酸を、誘導多能性幹細胞を製造できる核酸として選択する工程。 - 誘導多能性幹細胞が誘導されることを、NANOG遺伝子、SOX2遺伝子、OCT3/4遺伝子、KLF4遺伝子、LIN28遺伝子、およびc-MYC遺伝子からなる群から選択される少なくとも1つの遺伝子の、発現の亢進により検出する請求項8のスクリーニング方法。
- 前記核酸が、マイクロRNAである、請求項8又は9に記載のスクリーニング方法。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/579,314 US8852941B2 (en) | 2010-02-18 | 2011-02-18 | Method for producing induced pluripotent stem cells |
JP2012500652A JP5840119B2 (ja) | 2010-02-18 | 2011-02-18 | 誘導多能性幹細胞の製造方法 |
EP11744730.0A EP2537930A4 (en) | 2010-02-18 | 2011-02-18 | METHOD FOR MANUFACTURING INDUCED PLURIPOTENT STRAIN CELL |
CN2011800195911A CN102884188A (zh) | 2010-02-18 | 2011-02-18 | 诱导性多能干细胞的制备方法 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2010-034008 | 2010-02-18 | ||
JP2010034008 | 2010-02-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011102444A1 true WO2011102444A1 (ja) | 2011-08-25 |
Family
ID=44483029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/053457 WO2011102444A1 (ja) | 2010-02-18 | 2011-02-18 | 誘導多能性幹細胞の製造方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US8852941B2 (ja) |
EP (1) | EP2537930A4 (ja) |
JP (1) | JP5840119B2 (ja) |
CN (1) | CN102884188A (ja) |
WO (1) | WO2011102444A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015522257A (ja) * | 2012-06-13 | 2015-08-06 | ステムジェント, インコーポレイテッドStemgent, Inc. | 多能性幹細胞を調製する方法 |
JP2015527083A (ja) * | 2012-09-07 | 2015-09-17 | チルドレンズ メディカル センター コーポレーション | 造血幹細胞特異的レポーターマウスおよびその使用 |
JP2016123339A (ja) * | 2014-12-26 | 2016-07-11 | ユニーテック株式会社 | 多能性幹細胞の品質診断方法及び診断キット、抗がん剤並びに疾患モデル動物 |
WO2022138964A1 (ja) * | 2020-12-25 | 2022-06-30 | 国立大学法人京都大学 | 体細胞からのナイーブ型ヒトiPS細胞製造方法 |
CN115975949A (zh) * | 2023-03-20 | 2023-04-18 | 天九再生医学(天津)科技有限公司 | 一种基于microRNA制备诱导性多能干细胞的方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015073625A2 (en) * | 2013-11-15 | 2015-05-21 | The Mclean Hospital Corporation | Synergistic genome-nonintegrating reprogramming by micrornas and transcription factors |
WO2016118824A1 (en) | 2015-01-22 | 2016-07-28 | Regenerative Medical Solutions, Inc. | Markers for differentiation of stem cells into differentiated cell populations |
CN106119206A (zh) * | 2016-06-28 | 2016-11-16 | 深圳爱生再生医学科技有限公司 | 诱导性多能干细胞及其制备方法 |
CN110268051A (zh) * | 2016-06-30 | 2019-09-20 | 江苏大学 | 一种重编程因子组合在三维重编程体系中诱导多能干细胞的方法 |
US11572544B2 (en) | 2017-06-14 | 2023-02-07 | The Children's Medical Center Corporation | Hematopoietic stem and progenitor cells derived from hemogenic endothelial cells by episomal plasmid gene transfer |
AU2021211713A1 (en) | 2020-01-23 | 2022-08-25 | The Children's Medical Center Corporation | Stroma-free T cell differentiation from human pluripotent stem cells |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006025802A1 (en) * | 2004-09-03 | 2006-03-09 | Agency For Science, Technology And Research | Method for maintaining pluripotency of stem/progenitor cells |
WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
WO2009075119A1 (ja) * | 2007-12-10 | 2009-06-18 | Kyoto University | 効率的な核初期化方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0316089D0 (en) * | 2003-07-09 | 2003-08-13 | Xo Bioscience Ltd | Differentiation method |
RU2323722C2 (ru) * | 2005-12-26 | 2008-05-10 | Валентин Викторович Петров | Фармацевтическая композиция для фотодинамической терапии и способ лечения онкологического заболевания с ее использованием |
US9683232B2 (en) | 2007-12-10 | 2017-06-20 | Kyoto University | Efficient method for nuclear reprogramming |
JP5626619B2 (ja) * | 2008-12-08 | 2014-11-19 | 国立大学法人京都大学 | 効率的な核初期化方法 |
CN101970664B (zh) | 2008-01-16 | 2013-08-21 | 林希龙 | 使用可诱导的重组核糖核酸因子生成不含肿瘤的类胚胎干细胞的多能性细胞 |
WO2011049099A1 (ja) | 2009-10-20 | 2011-04-28 | 国立大学法人大阪大学 | 癌幹細胞の製造方法 |
JP2011087475A (ja) | 2009-10-20 | 2011-05-06 | Osaka Univ | 未分化細胞の識別方法 |
CA2780726A1 (en) * | 2009-11-11 | 2011-05-19 | Tariq M. Rana | Method for generation and regulation of ips cells and compositions thereof |
WO2011105551A1 (ja) | 2010-02-26 | 2011-09-01 | 国立大学法人大阪大学 | 癌幹細胞の検出方法、及び癌の治療剤または再発予防剤 |
-
2011
- 2011-02-18 WO PCT/JP2011/053457 patent/WO2011102444A1/ja active Application Filing
- 2011-02-18 US US13/579,314 patent/US8852941B2/en active Active
- 2011-02-18 JP JP2012500652A patent/JP5840119B2/ja active Active
- 2011-02-18 EP EP11744730.0A patent/EP2537930A4/en not_active Withdrawn
- 2011-02-18 CN CN2011800195911A patent/CN102884188A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006025802A1 (en) * | 2004-09-03 | 2006-03-09 | Agency For Science, Technology And Research | Method for maintaining pluripotency of stem/progenitor cells |
WO2007069666A1 (ja) | 2005-12-13 | 2007-06-21 | Kyoto University | 核初期化因子 |
WO2009075119A1 (ja) * | 2007-12-10 | 2009-06-18 | Kyoto University | 効率的な核初期化方法 |
Non-Patent Citations (8)
Title |
---|
CELL, vol. 126, 2006, pages 663 - 676 |
JUDSON R.L. ET AL.: "Embryonic stem cell- specific microRNAs promote induced pluripotency.", NATURE BIOTECHNOLOGY, vol. 27, no. 5, May 2009 (2009-05-01), pages 459 - 461, XP002577534, DOI: doi:10.1038/nbt.1535 * |
MICHIYO KOYANAGI ET AL.: "Mouse - Hito Taisaibo no iPS Saiboka ni Kakawaru microRNA no Tansaku to sono Kino Kaiseki", BMB2008 (DAI 31 KAI THE MOLECULAR BIOLOGY SOCIETY OF JAPAN SOKAI - DAI 81 KAI ANNUAL MEETING OF THE JAPANESE BIOCHEMICAL SOCIETY GODO TAIKAI) KOEN YOSHISHU, 20 November 2008 (2008-11-20), pages 295 * |
MICHIYO KOYANAGI ET AL.: "Mouse Taisaibo no Shokika ni Kakawaru microRNA no Tansaku to sono Kino Kaiseki", BMB2007 (DAI 30 KAI THE MOLECULAR BIOLOGY SOCIETY OF JAPAN SOKAI - DAI 80 KAI ANNUAL MEETING OF THE JAPANESE BIOCHEMICAL SOCIETY GODO TAIKAI) KOEN YOSHISHU, 25 November 2007 (2007-11-25), pages 504 * |
NUCLEIC ACID RESEARCH, vol. 36, 2008, pages D154 - D158 |
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 107, 2010, pages 40 - 45 |
SCIENCE, vol. 322, 2008, pages 949 - 953 |
See also references of EP2537930A4 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015522257A (ja) * | 2012-06-13 | 2015-08-06 | ステムジェント, インコーポレイテッドStemgent, Inc. | 多能性幹細胞を調製する方法 |
JP2015527083A (ja) * | 2012-09-07 | 2015-09-17 | チルドレンズ メディカル センター コーポレーション | 造血幹細胞特異的レポーターマウスおよびその使用 |
US10080354B2 (en) | 2012-09-07 | 2018-09-25 | Children's Medical Center Corporation | Hematopoietic stem cell specific reporter mouse and uses thereof |
JP2016123339A (ja) * | 2014-12-26 | 2016-07-11 | ユニーテック株式会社 | 多能性幹細胞の品質診断方法及び診断キット、抗がん剤並びに疾患モデル動物 |
WO2022138964A1 (ja) * | 2020-12-25 | 2022-06-30 | 国立大学法人京都大学 | 体細胞からのナイーブ型ヒトiPS細胞製造方法 |
CN115975949A (zh) * | 2023-03-20 | 2023-04-18 | 天九再生医学(天津)科技有限公司 | 一种基于microRNA制备诱导性多能干细胞的方法 |
CN115975949B (zh) * | 2023-03-20 | 2023-09-01 | 天九再生医学(天津)科技有限公司 | 一种基于microRNA制备诱导性多能干细胞的方法 |
Also Published As
Publication number | Publication date |
---|---|
JP5840119B2 (ja) | 2016-01-06 |
JPWO2011102444A1 (ja) | 2013-06-17 |
EP2537930A4 (en) | 2013-10-02 |
US8852941B2 (en) | 2014-10-07 |
EP2537930A1 (en) | 2012-12-26 |
US20130065243A1 (en) | 2013-03-14 |
CN102884188A (zh) | 2013-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5840119B2 (ja) | 誘導多能性幹細胞の製造方法 | |
US9353352B2 (en) | Embryonic stem cell specific microRNAs promote induced pluripotency | |
Gai et al. | Generation and characterization of functional cardiomyocytes using induced pluripotent stem cells derived from human fibroblasts | |
van Laake et al. | Reporter-based isolation of induced pluripotent stem cell–and embryonic stem cell–derived cardiac progenitors reveals limited gene expression variance | |
JP2018075017A (ja) | 神経幹細胞および運動ニューロンの生成 | |
US20150232810A1 (en) | Methods of preparing pluripotent stem cells | |
AU2016250905B2 (en) | Generation of muscle-lineage cells from stem cells | |
KR102202160B1 (ko) | 조직 구조체 및 그 제작 방법 | |
JP6893633B2 (ja) | 分化細胞の抽出方法 | |
Vitaloni et al. | MicroRNAs contribute to induced pluripotent stem cell somatic donor memory | |
EP3372681A1 (en) | Immortalized stem cells, and method for producing same | |
KR20150035594A (ko) | 합성 메신저 rna에 의한 인간 유도 만능 줄기 세포의 피더프리 유래 | |
WO2021172542A1 (ja) | 成熟心筋細胞の製造法 | |
JP6906231B2 (ja) | アストロサイト様細胞及びその調製方法 | |
Gong et al. | Interplay of transcription factors and microRNAs during embryonic hematopoiesis | |
KR101548534B1 (ko) | 전자기장을 이용한 성체세포를 유도만능 줄기세포로 역분화시키는 방법 | |
JP2011004674A (ja) | 誘導多能性幹細胞(iPS細胞)の製造方法 | |
Ojala et al. | Modeling Hypertrophic Cardiomyopathy with Human Induced Pluripotent Stem Cells | |
Haneef | Effect of valproic acid on the hepatic differentiation of mesenchymal stem cells in 2D and 3D microenvironments | |
US20130273655A1 (en) | ENGRAFTMENT POTENTIAL OF EMBRYONIC STEM CELLS AND PLURIPOTENT STEM CELLS USING MICRO RNAs | |
JP7362097B2 (ja) | 細胞特異的にヌクレアーゼを制御する方法 | |
Krems et al. | Marlene Geyer | |
Meader | Understanding the role of miRNA expression in the differentiation of haematopoietic stem cells from pluripotent stem cells | |
Frobel | DNA methylation changes in hematopoietic development and iPSC-derived model systems | |
Nguyen Nhi | Expression and Biological Role of the Chromosome 19 Microrna Cluster (C19MC) in Stem Cell Pluripotency |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201180019591.1 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11744730 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2012500652 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2011744730 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011744730 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13579314 Country of ref document: US |